---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-003449"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2022-02-02T23:59:59+00:00"
generated_at: "2026-06-27T12:39:58.465985+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# IDEXX Q4 revenue $801M (+11%), full-year EPS $8.60 (+28%); guides 2022 revenue $3.5-$3.565B

## Summary
- Q4 revenue $801M, up 11% reported and 10.5% organic; CAG Diagnostics recurring revenue grew 13%.
- Full-year EPS $8.60, up 28% reported and 29% comparable; operating margin expanded 330 bps reported.
- Record premium instrument placements drove 14% YoY expansion of global installed base.
- Initial 2022 guidance: revenue $3,500M-$3,565M (9-11% growth), EPS $9.27-$9.59 (8-11% growth).
- U.S. same-store clinical visit growth 2% in Q4; on a two-year basis, visits up 5.5%.

## SEC filing metadata
- accession: 0001564590-22-003449
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2022-02-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000156459022003449/0001564590-22-003449-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000156459022003449/idxx-8k_20220202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-003449
- JSON: https://secwatch.observer/filing/0001564590-22-003449.json
- Plain text: https://secwatch.observer/filing/0001564590-22-003449.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.